Plain-English translation of NCT04139304 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment approach for plasmablastic lymphoma, a rare and aggressive blood cancer. The study combines a drug called with a chemotherapy regimen to see if this combination is safe and effective. Researchers want to learn whether this new approach can help patients with this serious diagnosis.
Plasmablastic lymphoma is a rare and difficult-to-treat cancer, especially in people with HIV. Current treatments don't work well for everyone, so doctors are testing whether adding this newer immunotherapy medication to standard chemotherapy can improve outcomes and help more patients achieve remission.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive six cycles of treatment, given every 3 weeks. Each cycle involves an infusion of the new medication at the start and during the first few weeks, plus intravenous chemotherapy over 4 days and an oral steroid medication. After treatment ends, you'll have follow-up visits every 3 months for up to 2 years to monitor your health and how well the treatment worked.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States